Growth hormone replacement therapy in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial

医学 射血分数 安慰剂 心力衰竭 随机对照试验 心脏病学 激素替代疗法(女性对男性) 内科学 替代医学 病理 睾酮(贴片)
作者
Alberto M. Marra,Roberta D’Assante,M De Luca,Michele Arcopinto,Stefania Paolillo,Valéria Valente,Giulia Crisci,Dario Bruzzese,Stefania Paolillo,Pasquale Perrone Filardi,Giovanna Esposito,Eduardo Bossone,Andrea Salzano,Antonio Cittadini
出处
期刊:European Journal of Preventive Cardiology [Oxford University Press]
卷期号:32 (Supplement_1)
标识
DOI:10.1093/eurjpc/zwaf236.038
摘要

Abstract Background Preliminary results of GH deficiency (GHD) correction in Heart Failure (HF) showed an improvement in quality of life, cardiac architecture and function, and cardiovascular performance. Aim of the present double-blind, randomized, placebo-controlled trial was to evaluate the cardiovascular effects of 1 year of GH replacement therapy in a cohort of patients with heart failure and reduced ejection fraction (HFrEF). Methods Consecutive patients with HFrEF in NYHA class I/II/III and concomitant GHD were recruited. GHD patients were randomized to receive GH, (0.012 mg/kg every second day ~2.5 IU), or placebo, on top of background therapy. The primary endpoint was peak oxygen consumption (peak VO2). Secondary endpoints included hospitalizations, end-systolic LV volumes, NT-proBNP levels and Health-related Quality of Life score. Results The study groups consisted of 64 patients, 30 randomized in the active treatment group, and 34 in the control group. After 1 year, a statistically significant improvement of peak VO2 was reached in the active group (from 12.8±3.4 to 15.5±3.15mL/Kg/min, p<0.01; Δ peak VO2 between groups: +3.1 vs -1.8 p<0.01, see figure 1). GH improved LV and RV function (i.e. LV ejection fraction, TAPSE and TAPSE/PASP ratio, p<0.01), leading to an amelioration of clinical status (NYHA class, p<0.05) and health-related quality of life (MLWHFQ, p<0.05). A significant decrease of NT-proBNP was also found (p<0.05). Conclusions This randomized, double-blind, placebo-controlled trial demonstrates that GH replacement therapy in HFrEF patients with GHD improves exercise performance, and LV and RV architecture and function, leading to an amelioration of clinical status and health-related quality of life.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
小羊完成签到 ,获得积分10
1秒前
羰醛完成签到,获得积分10
1秒前
天天快乐的应助被开心德地采纳,获得10
1秒前
2秒前
3秒前
扯纸大王完成签到,获得积分10
3秒前
3秒前
沉默的板凳完成签到,获得积分10
4秒前
4秒前
5秒前
小巧妙梦发布了新的文献求助10
5秒前
CXY发布了新的文献求助10
5秒前
梦璃完成签到 ,获得积分10
6秒前
6秒前
6秒前
共享精神的应助被ally采纳,获得10
6秒前
老年人发布了新的文献求助10
7秒前
7秒前
瘦瘦草丛发布了新的文献求助10
7秒前
云海完成签到,获得积分10
8秒前
称心学姐完成签到 ,获得积分10
8秒前
852的应助被00采纳,获得10
9秒前
9秒前
bkagyin的应助被开心德地采纳,获得10
9秒前
李易峰发布了新的文献求助10
9秒前
pretty完成签到 ,获得积分10
9秒前
9秒前
9秒前
Hongjun发布了新的文献求助10
9秒前
科研通AI6.2的应助被xiao xu采纳,获得10
9秒前
10秒前
NexusExplorer的应助被研白采纳,获得10
10秒前
10秒前
10秒前
马到成功发布了新的文献求助10
10秒前
微血管发布了新的文献求助10
11秒前
共享精神的应助被绘海采纳,获得10
11秒前
kk发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187707
求助须知:如何正确求助?哪些是违规求助? 9575782
关于积分的说明 21843037
捐赠科研通 7785576
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2481986